** Shares of ASX-listed Mesoblast MSB.AX rise 2.88% to A$2.14, set for third session of consecutive gains — if trends hold

** Stock among the biggest percentage gainers in the ASX200 index .AXJO

** Biotech releases pricing information for its product Ryoncil, used to treat a serious condition called graft-versus-host disease, which can happen after a person gets a blood cell transplant

** Treatment centres can now order kits tailored to the appropriate dosage for each patient, with pricing applied uniformly, regardless of patient weight — MSB

** Pricing details for Ryoncil are now available in all four major drug pricing compendia in the United States

** Says that this follows approval and publication by the U.S. Food and Drug Administration of the revised Ryoncil label, which includes revisions to the product prescribing information

** Stock down 31.3% YTD including current session

(Reporting by Kumar Tanishk in Bengaluru)

((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk))